Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 ESSA PharmaProthenaVeruHumanigenMannKind
SymbolNASDAQ:EPIXNASDAQ:PRTANASDAQ:VERUNASDAQ:HGENNASDAQ:MNKD
Price Information
Current Price$24.82$24.85$9.42$14.73$4.18
52 Week RangeBuyBuyBuyBuyBuy
MarketRank™
Overall Score1.62.11.41.71.4
Analysis Score2.53.53.53.43.5
Community Score3.12.82.93.52.2
Dividend Score0.00.00.00.00.0
Ownership Score2.53.30.00.80.8
Earnings & Valuation Score0.00.60.60.60.6
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyBuy
Consensus Price Target$28.80$29.43$19.20$29.83$6.63
% Upside from Price Target16.04% upside18.42% upside103.82% upside102.53% upside58.49% upside
Trade Information
Market Cap$838.42 million$994.15 million$677.41 million$787.79 million$1.04 billion
Beta1.961.710.71-0.792.28
Average Volume360,379460,1583,806,4192,514,6985,835,671
Sales & Book Value
Annual RevenueN/A$810,000.00$42.59 millionN/A$63.04 million
Price / SalesN/A1,227.3415.91N/A16.52
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$2.47 per share$6.84 per share$0.43 per share($0.63) per share($0.92) per share
Price / BookN/A3.6321.91N/A-4.54
Profitability
Net Income$-23,440,000.00$-77,680,000.00$-18,970,000.00$-10,290,000.00$-51,900,000.00
EPS($1.04)($1.95)($0.11)N/A($0.27)
Trailing P/E RatioN/AN/AN/A0.00N/A
Forward P/E RatioN/AN/AN/A3.59N/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/A-13,615.75%-44.55%N/A-71.92%
Return on Equity (ROE)-46.31%-41.97%-23.72%-302.90%N/A
Return on Assets (ROA)-45.08%-26.26%-13.80%-174.74%-46.80%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/AN/AN/AN/A
Current Ratio66.75%14.75%1.83%6.19%0.63%
Quick Ratio66.75%14.75%1.38%6.19%0.58%
Ownership Information
Institutional Ownership Percentage63.37%90.15%23.32%30.18%29.60%
Insider Ownership PercentageN/A30.40%26.10%37.50%1.09%
Miscellaneous
Employees256633910240
Shares Outstanding33.78 million40.01 million71.91 million53.48 million249.07 million
Next Earnings Date5/6/2021 (Estimated)5/5/2021 (Estimated)5/12/2021 (Estimated)5/21/2021 (Estimated)5/5/2021 (Estimated)
OptionableNot OptionableOptionableOptionableOptionableOptionable
SourceHeadline
MannKind Corporation (MNKD) has great growth outlook for 2021MannKind Corporation (MNKD) has great growth outlook for 2021
marketingsentinel.com - April 14 at 12:20 AM
This Week At the Ninth: Surgical Robots and Scienter - JD SupraThis Week At the Ninth: Surgical Robots and Scienter - JD Supra
jdsupra.com - April 12 at 11:47 PM
MNKD Apr 2021 2.000 callMNKD Apr 2021 2.000 call
finance.yahoo.com - April 12 at 6:47 PM
MannKind Corporation [MNKD] gain 35.46% so far this year. What now?MannKind Corporation [MNKD] gain 35.46% so far this year. What now?
dbtnews.com - April 12 at 6:47 PM
Last Week At The Ninth: Surgical Robots And Scienter - Litigation, Mediation & Arbitration - United States - Mondaq News AlertsLast Week At The Ninth: Surgical Robots And Scienter - Litigation, Mediation & Arbitration - United States - Mondaq News Alerts
mondaq.com - April 12 at 1:46 PM
Drugmaker MannKind Escapes Investors Suit At 9th Circ. - Law360Drugmaker MannKind Escapes Investors' Suit At 9th Circ. - Law360
law360.com - April 9 at 10:39 PM
Plausible Motive Averment Weighty in Securities Fraud Action - Metropolitan News-EnterprisePlausible Motive Averment Weighty in Securities Fraud Action - Metropolitan News-Enterprise
metnews.com - April 9 at 12:35 PM
Biopharma Investors Fail to Revive Suit on Bank Analysts Report - Bloomberg LawBiopharma Investors Fail to Revive Suit on Bank Analyst's Report - Bloomberg Law
news.bloomberglaw.com - April 8 at 9:20 PM
3 Biotech Penny Stocks To Watch In April 2021 - StreetInsider.com3 Biotech Penny Stocks To Watch In April 2021 - StreetInsider.com
streetinsider.com - April 7 at 12:26 PM
3 Biotech Penny Stocks To Watch In April 2021 | FinancialContent Business Page - Financial Content3 Biotech Penny Stocks To Watch In April 2021 | FinancialContent Business Page - Financial Content
markets.financialcontent.com - April 6 at 7:57 PM
NeuroRx Announces Zyesami Has Been Selected for Inclusion in NIH-Sponsored Global Clinical Trial to Include Aviptadil and Remdesivir - Investing News NetworkNeuroRx Announces Zyesami Has Been Selected for Inclusion in NIH-Sponsored Global Clinical Trial to Include Aviptadil and Remdesivir - Investing News Network
investingnews.com - April 6 at 9:37 AM
MannKind (NASDAQ: MNKD) Expected to Post $16.08M Quarterly Sales - The Union JournalMannKind (NASDAQ: MNKD) Expected to Post $16.08M Quarterly Sales - The Union Journal
theunionjournal.com - April 5 at 1:11 PM
Is MannKind (MNKD) Ready to Hit $10 After The Breakout? – Own Snap - Own SnapIs MannKind (MNKD) Ready to Hit $10 After The Breakout? – Own Snap - Own Snap
ownsnap.com - April 4 at 12:35 PM
Global Dry Powder Inhaler Devices Pipeline Assessment Report 2020: Major Players, Product Description, Licensing and Collaboration Details and Developmental Activities - ResearchAndMarkets.com - Business WireGlobal Dry Powder Inhaler Devices Pipeline Assessment Report 2020: Major Players, Product Description, Licensing and Collaboration Details and Developmental Activities - ResearchAndMarkets.com - Business Wire
businesswire.com - April 2 at 12:58 PM
United Therapeutics to extend Tyvasos reach with expanded label - BioWorld OnlineUnited Therapeutics to extend Tyvaso's reach with expanded label - BioWorld Online
bioworld.com - April 1 at 7:51 PM
MannKind (NASDAQ:MNKD) Stock Price Up 8.7%MannKind (NASDAQ:MNKD) Stock Price Up 8.7%
americanbankingnews.com - April 1 at 3:42 PM
MannKind Co. (NASDAQ:MNKD) Short Interest Up 68.2% in MarchMannKind Co. (NASDAQ:MNKD) Short Interest Up 68.2% in March
americanbankingnews.com - March 30 at 4:36 PM
MannKind Co. (NASDAQ:MNKD) Given Consensus Rating of "Buy" by AnalystsMannKind Co. (NASDAQ:MNKD) Given Consensus Rating of "Buy" by Analysts
americanbankingnews.com - March 30 at 6:38 AM
Top Penny Stocks To Watch This Week If You Like Biotech Stocks - Financial ContentTop Penny Stocks To Watch This Week If You Like Biotech Stocks - Financial Content
markets.financialcontent.com - March 29 at 7:07 PM
MNKD Apr 2021 7.500 putMNKD Apr 2021 7.500 put
au.finance.yahoo.com - March 29 at 2:07 PM
Insider Trading At MannKind Corporation (NASDAQ:MNKD): What Did We Note?Insider Trading At MannKind Corporation (NASDAQ:MNKD): What Did We Note?
stocksregister.com - March 26 at 5:54 PM
MannKind Corporation (MNKD) Stock:Do Analysts Think You Should Sell? - InvestorsObserverMannKind Corporation (MNKD) Stock:Do Analysts Think You Should Sell? - InvestorsObserver
investorsobserver.com - March 26 at 1:43 AM
MannKind (NASDAQ:MNKD) Trading Up 3.7%MannKind (NASDAQ:MNKD) Trading Up 3.7%
americanbankingnews.com - March 25 at 11:36 AM
Analysts Are Bullish on These Healthcare Stocks: Ascendis Pharma (ASND), Flexion Therapeutics (FLXN) - Smarter AnalystAnalysts Are Bullish on These Healthcare Stocks: Ascendis Pharma (ASND), Flexion Therapeutics (FLXN) - Smarter Analyst
smarteranalyst.com - March 18 at 10:39 AM
MannKind Corporations $230 Million Notes Offering – Global Legal Chronicle - Global Legal ChronicleMannKind Corporation's $230 Million Notes Offering – Global Legal Chronicle - Global Legal Chronicle
globallegalchronicle.com - March 17 at 10:38 PM
DateCompanyBrokerageAction
3/10/2021ESSA PharmaPiper SandlerInitiated Coverage
3/3/2021ESSA PharmaHC WainwrightLower Price Target
2/12/2021ESSA PharmaBloom BurtonReiterated Rating
2/11/2021ESSA PharmaOppenheimerBoost Price Target
11/2/2020ESSA PharmaJefferies Financial GroupInitiated Coverage
2/26/2021ProthenaRoyal Bank of CanadaUpgrade
2/2/2021ProthenaBTIG ResearchUpgrade
10/21/2020ProthenaCantor FitzgeraldBoost Price Target
5/10/2020ProthenaNomuraReiterated Rating
1/1/2020ProthenaNomura SecuritiesReiterated Rating
12/22/2019ProthenaEvercore ISIReiterated Rating
5/31/2019ProthenaBarclaysReiterated Rating
12/14/2020VeruBrookline Capital ManagementBoost Price Target
3/20/2019VeruCIBCInitiated Coverage
3/29/2021HumanigenRoth CapitalBoost Price Target
2/23/2021HumanigenJPMorgan Chase & Co.Initiated Coverage
12/23/2020HumanigenNational SecuritiesInitiated Coverage
3/11/2021MannKindSVB LeerinkBoost Price Target
6/15/2018MannKindMaxim GroupReiterated Rating
(Data available from 4/17/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.